HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
北海道大学病院  >
雑誌発表論文等  >

The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma

フルテキスト
JG44-9_p991-999.pdf369.1 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/39478

タイトル: The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma
著者: Chuma, Makoto 著作を一覧する
Hige, Shuhei 著作を一覧する
Kamiyama, Toshiya 著作を一覧する
Meguro, Takashi 著作を一覧する
Nagasaka, Atsushi 著作を一覧する
Nakanishi, Kazuaki 著作を一覧する
Yamamoto, Yoshiya 著作を一覧する
Nakanishi, Mitsuru 著作を一覧する
Kohara, Toshihisa 著作を一覧する
Sho, Takuya 著作を一覧する
Yamamoto, Keiko 著作を一覧する
Horimoto, Hiromasa 著作を一覧する
Kobayashi, Tomoe 著作を一覧する
Yokoo, Hideki 著作を一覧する
Matsushita, Michiaki 著作を一覧する
Todo, Satoru 著作を一覧する
Asaka, Masahiro 著作を一覧する
キーワード: Hepatocellular carcinoma
Hepatitis B virus
Recurrence
Antiviral therapy
発行日: 2009年 9月
出版者: Springer Japan
誌名: Journal of Gastroenterology
巻: 44
号: 9
開始ページ: 991
終了ページ: 999
出版社 DOI: 10.1007/s00535-009-0093-z
抄録: Background. Prediction and prevention of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) recurrence is an important clinical issue. We investigated whether HBV DNA level and antiviral therapy are associated with HCC recurrence. Methods. This retrospective study involved 103 patients who underwent hepatic resection or radiofrequency ablation for initial HCC. Patients were divided into four groups. Thirty had high serum HBV DNA levels (>4 log10 copies/mL) and had not received antiviral therapy (high virus group; HVG). Thirty-four had low HBV DNA levels (≤4 log10 copies/mL) and had not received antiviral therapy (low virus group; LVG). Twenty received antiviral therapy after HCC developed (therapeutic group A, TG-A). Nineteen received antiviral therapy before HCC developed (therapeutic group B, TG-B). Results. Cumulative HCC recurrence rates at 3 years in the HVG, LVG, TG-B, and TG-A were 71.1%, 42.2%, 42.3%, and 52.0%, respectively. Recurrence rates differed significantly between the HVG and LVG (P = 0.016) and between the HVG and TG-B (P = 0.008). Recurrence rate in the TG-A was marginally lower than in the HVG (P = 0.10). On multivariate analysis, high serum hepatitis B virus DNA levels (hazard ratio: HR, 2.67; 95% CI, 1.31-5.47; P = 0.007) and absence of antiviral therapy (HR, 2.57; 95% CI, 1.34-4.94; P = 0.005) were independent risk factors for hepatocellular carcinoma recurrence. Conclusion. HBV DNA level and antiviral therapy are associated with HCC recurrence. For patients with high HBV DNA levels, antiviral therapy before the development of HCC is important for prevention of recurrence.
Rights: The original publication is available at www.springerlink.com
資料タイプ: article (author version)
URI: http://hdl.handle.net/2115/39478
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 中馬 誠

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学